Trial Profile
The Prostate CARE Study: Capecitabine (Xeloda) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and phase II efficacy study.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 29 Aug 2011
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Rhenium-188-etidronic acid (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Prostate CARE Study
- 29 Aug 2011 New trial record